Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Rosalia Quezada Urban und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Single-Cell Analysis, Transcriptome, Cell Differentiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rotary Club of Manningham, Melbourne Research Scholarship, Peter MacCallum Foundation.
Abstract (Originalsprache)
Neuroendocrine prostate cancer (NEPC) tumours are classified by pathology into several distinct subtypes. Gene expression profiling has revealed transcriptional heterogeneity across NEPC, but this is rarely considered in the context of variation between pathologies. Diagnosis typically relies on immunohistochemical markers (CHGA, SYP, NCAM1) and genomic alterations in RB1, PTEN and TP53. We hypothesized that NEPC pathologies have unique transcriptional features. Single‐cell RNA sequencing of 18 632 tumour cells from nine patient‐derived xenograft models representing five pathologies (small‐cell and large‐cell neuroendocrine carcinomas, focal neuroendocrine differentiation (Focal NED), low‐grade neuroendocrine and amphicrine) demonstrated pathway‐specific enrichment. Focal NED and amphicrine tumours exhibited cellular subpopulations enriched for KRAS, IL2‐STAT5 and TNF signalling pathways, absent in small‐ and large‐cell carcinomas, which were instead enriched for Myc and E2F pathways. Furthermore, focal NED cells exhibited minimal clonal divergence from adjacent adenocarcinoma cells, while small cell carcinoma cells were clonally distinct. These data underscore significant transcriptional variation among NEPC pathologies, highlighting focal NED's unique biological context and its clinical implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
- Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Australia.
- Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, Australia.
- TissuPath Pathology Ltd, Mount Waverley, Australia.
ORCID-Profile: David L Goode
Förderung
- Rotary Club of Manningham
- Melbourne Research Scholarship
- Peter MacCallum Foundation
- Sistema Nacional de Investigadores
- Victorian Cancer Agency
- Cancer Council Victoria
- EJ Whitten Foundation
- National Health and Medical Research Council
Zitieren
APA
Quezada Urban, R., Keerthikumar, S., Clark, A., Wang, H., Phipson, B., Bakshi, A., Ryan, A., Thorne, H., Taylor, R. A., Lawrence, M. G., Risbridger, G. P., Toivanen, R., & Goode, D. L. (2025). Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology. Molecular Oncology. https://doi.org/10.1002/1878-0261.70099
Vancouver
Quezada Urban R, Keerthikumar S, Clark A, Wang H, Phipson B, Bakshi A, et al. Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology. Molecular Oncology. 2025. doi:10.1002/1878-0261.70099
BibTeX
@article{QuezadaUrban2025,
author = {Quezada Urban, Rosalia and Keerthikumar, Shivakumar and Clark, Ashlee and Wang, Hong and Phipson, Belinda and Bakshi, Andrew and Ryan, Andrew and Thorne, Heather and Taylor, Renea A and Lawrence, Mitchell G and Risbridger, Gail P and Toivanen, Roxanne and Goode, David L},
title = {Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70099}
}
EUVIMED